
Elizabeth C Verna
Marina Serper
Jaime Chu
Kathleen Corey
Oren K Fix

Swedish Medical Center, Seattle, WA, United States

See next page for additional authors

Follow this and additional works at: https://digitalcommons.psjhealth.org/publications

Part of the Hepatology Commons, and the Infectious Disease Commons

Recommended Citation
Verna, Elizabeth C; Serper, Marina; Chu, Jaime; Corey, Kathleen; Fix, Oren K; Hoyt, Karen; Page, Kimberly A; Loomba, Rohit; Li, Ming; Everson, Gregory T; Fried, Michael W; Garcia-Tsao, Guadalupe; Terrault, Norah; Lok, Anna S; Chung, Raymond T; and Reddy, K Rajender, "Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation." (2020). Articles, Abstracts, and Reports. 3559.
https://digitalcommons.psjhealth.org/publications/3559

This Article is brought to you for free and open access by Providence St. Joseph Health Digital Commons. It has been accepted for inclusion in Articles, Abstracts, and Reports by an authorized administrator of Providence St. Joseph Health Digital Commons. For more information, please contact digitalcommons@providence.org.
Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation

Elizabeth C. Verna¹, Marina Serper², Jaime Chu³, Kathleen Corey⁴, Oren K. Fix⁵, Karen Hoyt⁶, Kimberly A. Page⁷, Rohit Loomba⁸, Ming Li⁹, Gregory T. Everson¹⁰, Michael W. Fried¹¹, Guadalupe Garcia-Tsao¹², Norah Terrault⁹, Anna S. Lok¹³, Raymond T. Chung⁴, K. Rajender Reddy²

¹Center for Liver Disease and Transplantation, Columbia University Irving Medical Center, New York, NY
²University of Pennsylvania, Philadelphia, PA
³Mt. Sinai School of Medicine, New York, NY
⁴Liver Center, Massachusetts General Hospital, Boston, MA
⁵Swedish Medical Center, Seattle, WA

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/HEP.31491

This article is protected by copyright. All rights reserved
Address correspondence to:

K. Rajender Reddy M.D
Division of Gastroenterology and Hepatology
University of Pennsylvania
2, Dulles, 3400 Spruce Street
Philadelphia, PA 19104
Tel No. 215-662-4276
E-mail: reddy@pennmedicine.upenn.edu
Abbreviations:

COVID-19: Coronavirus disease 2019
SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2
NIH: National Institutes of Health
NASH: Non-alcoholic steatohepatitis
HALT-C: Hepatitis C Antiviral Long-Term Treatment against Cirrhosis
FDA: Food and Drug Administration
VA: Veterans Administration
MVP: Million Veterans Program
EMA: European Medicines Agency
VA CDW: VA Corporate Data Warehouse
VA ORD: VA Office of Research and Development
IDE: Investigational Device Exemption
IRB: Institutional Review Board
EHR: Electronic Health Record
EUA: Emergency Use Authorization
BSL-3: Biosafety Level 3
BA: Biliary atresia
ChiLDReN: The Childhood Liver Disease Research Network

This article is protected by copyright. All rights reserved
NAFLD: Non-alcoholic fatty liver disease

SPLIT-TTS: Society of Pediatric Liver Transplantation – The Transplantation Society

NASPGHAN: North American Society For Pediatric Gastroenterology, Hepatology & Nutrition

IP: Investigational Product

PRO: Patient Reported Outcomes

Disclosure:
EV- Research grant support (to Institution) Salix; Advisory Board Gilead
MS-None
JC-None
KC-Served in scientific advisory boards for Novo Nordisk, BMS and Boehringer-Ingelheim
OF-None
KH-None
KP-None
RL-Consultant or advisory board member for 89bio, Alnylam, Arrowhead Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol-Myer Squibb, Cirius, CohBar, DiCerna, Galmed, Gilead, Glymphse bio, Intercept, Ionis, Metacrine, NGM Biopharmaceuticals, Novo Nordisk, Pfizer, Sagimet and Viking Therapeutics. In addition, his Institution has received grant support from Allergan, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Galmed Pharmaceuticals, Genfit, Gilead, Intercept, Inventiva, Janssen, Madrigal Pharmaceuticals, NGM Biopharmaceuticals, Novartis, Pfizer, pH Pharma, and Siemens. He is also co-founder of Liponexus, Inc. Funding Statement: RL receives funding support from NIEHS (5P42ES010337), NCATS (5UL1TR001442), NIDDK (R01DK106419, 1R01DK121378, R01 DK124318, P30DK120515), and DOD PRCRP (CA170674P2).
ML-None
GTE is an equity member and CEO of HepQuant LLC.
MWF-Receives fees and is a stockholder in TARGET PharmaSolutions
GG-T-None
NT-Research grant support (to Institution) from Gilead and Roche/Genentech
ASL-None
RTC-Research grant support (to Institution) Abbvie, Gilead, Merck, BMS, Janssen,
Boehringer-Ingelheim, Roche, Kaleido, Synlogic
KRR-Advisory Board- Mallinckrodt, Gilead. Research support (to Institution)-Mallinckrodt, Grifols,
Gilead, Merck, BMS, Intercept, Exact Sciences, NASH-TARGET, HCC-TARGET

Funding Source: None
Abstract:

The SARS-CoV-2 pandemic has drastically altered all facets of clinical care and research. Clinical research in hepatology has had a rich tradition in several domains, including the discovery and therapeutic development for diseases such as hepatitis B and C, and studying the natural history of many forms of chronic liver disease. NIH, foundation and industry funding has provided important opportunities to advance the academic careers of young investigators while they strived to make contributions to the field. Instantaneously, however, all non-essential research activities were halted when the pandemic started, forcing those involved in clinical research to re-think their research strategy, including a shift to COVID-19 research while endeavoring to maintain their pre-existing agenda. Strategies to maintain the integrity of ongoing studies, including patient follow up, safety assessments and continuation of investigation products, have included a shift to telemedicine, remote safety laboratory monitoring, and shipping of investigational products to study subjects. As a re-vamp of research is being planned, unique issues that face the research community include maintenance of infrastructure, funding, completion of studies in the pre-determined time frame and the need to re-program career path timelines. Real world databases, biomarker and long term follow up studies, and research involving special groups (children, the homeless and other marginalized populations) are likely to face unique challenges. The implementation of telemedicine has been dramatically accelerated and will serve as a backbone for the future of clinical research. As we move forward, innovation in clinical trial design will be essential for conducting optimized clinical research.

Introduction:
The impact of coronavirus disease 2019 (COVID-19) on clinical research has been felt variably across the world, though there are several unique considerations in the US. Clinical research in every domain of medicine during the early phases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic came to a halt, and has been largely relegated to a non-essential activity. Appropriately, the shift has been towards COVID-19-related research, including an accelerated strategy for developing and validating diagnostic tests, vaccines, and therapeutics. As such, non-essential research, including NIH- and pharmaceutical industry-sponsored clinical trials, longitudinal biorepositories and real world research studies, have faced significant challenges.

Clinical research in hepatology has a rich and long tradition of developing therapies through rigorously conducted trials for conditions such as chronic hepatitis B and C, and now non-alcoholic steatohepatitis (NASH)(1-3). Historically, materials from biorepositories have also led to important observations; serum collected after an outbreak of icteric hepatitis in Army personnel in 1942 linked to contaminated yellow fever vaccine allowed for subsequent recognition that this outbreak was due to hepatitis B(4). Long term trials that allow for description of disease natural history, such as Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) study, have made essential observations that continue to inform clinical practice(5). Real life studies have provided an opportunity to address therapeutic outcomes in challenging populations and to compare standard of care therapeutic approaches(6). Further, real-world data have provided much needed information on patient characteristics and care outside of the clinical trial environment where patients are carefully selected, and have generated post-marketing safety and clinical effectiveness data post approval of hepatitis C therapy, allowing for the critical evaluation by the Food and Drug Administration (FDA)(7). In addition, the Veterans Administration (VA) research over decades has made sentinel observations relevant to clinical practice while providing an enormous biorepository through the Million Veterans Program (MVP)(8-10).

Hepatology clinical research was halted when the pandemic took hold, and uncertainty in the timing and pace of reentry has created additional challenges. Perhaps more importantly, what the long-term post-pandemic era of “the new normal” state will hold is unknown. In the immediate future, prospects for maintenance of current research funding and infrastructure are uncertain as the community struggles with maintaining safe practice procedures to minimize the risk of transmission of COVID-19. Clinical care revenue and foundation/association endowments, which have been vital to support unfunded and investigator-initiated research, have also been considerably impacted. Thus, as investigators, it is important that we recognize these challenges, position ourselves for anticipated changes, and become innovative in order to achieve our research mission. These challenges have also created important opportunities, and have already led to accelerated integration of telehealth into research practices, and expanded the potential of real world datasets to rapidly disseminate knowledge as the pandemic evolved.
Continued growth will require partnering with several stakeholders, including investigators, patients, information technology, industry, and national and international partners such as the FDA, European Medicines Agency (EMA) and NIH. This document endeavors to provide insights into the current status of clinical research in several domains of hepatology (Figure 1), as well as its challenges and direction it might be heading in, during and following the COVID-19 pandemic (Table 1).

**Investigational Product (IP), Clinical, and Device Trials:**

**Sponsored Clinical Trials**

As SARS-CoV-2 made its way to the U.S., research centers within and outside academic institutions quickly moved to close down non-essential activities, including face-to-face study visits and cessation of enrollment in new clinical trials. Investigators were required to determine which research visits were essential for safety purposes; clinical research infrastructure shifted to focus on supporting COVID-19-related research. For many, the loss of clinical research support staff and facilities made conducting even the essential safety visits challenging. Existing clinical trials had to adjust expectations – shifting to telemedicine visits, less reliance on laboratory or other invasive monitoring, and less collection of biospecimens for ancillary studies. The hard truth is that many active clinical trials have missed collection of critical study data that in turn may influence the successful and timely completion and interpretation of studies. Due to exceptional circumstances protocol deviations/violations will likely be more frequent, and adverse events may also be more common but causality assessment due to COVID-19 as a confounder can be challenging. It is very likely that extension of data collection post-COVID-19 to capture critical safety and efficacy data may be needed. Both from the standpoint of regulatory agencies and the journals publishing study results, consideration of the impact of protocol deviations on the study outcomes and conclusions will be necessary.

As institutions reopen clinical activities and clinical research, the trajectory for clinical trials faces uncertainties. First, research staff, ancillary study services and study participants need to be assured of a safe environment to conduct research. This will be stepwise and variable in pace across the U.S. The focus will be initially on resuming work on clinical trials already underway and any new study would need a COVID-19 contingency plan. Going forward, clinical trials should consider provisions for telemedicine visits, remote monitoring, use of services for remote collection of biospecimens and plans for direct delivery of investigational product to participants. Second, the COVID-19 experience has served to highlight what is essential versus what is aspirational with regards to data and biospecimen collection.
Clinical trials may need to focus more on the essential and less on the aspirational for the near future. Third, the research community needs to consider the impact of COVID-19 on patients’ willingness to participate in clinical trials(11) with efforts made to assure participants that their safety has been and remains a primary focus. Indeed, COVID-19 may provide an opportunity to highlight the role of clinical research in healthcare advances. The importance of well-designed clinical trials as a means of informing best practices – even under the threat of a pandemic – can be highlighted.

The long-term impact of COVID-19 on clinical trials is difficult to quantify, but is likely to be measured in years, even though the initial shut-down was only for a few months. This reflects the time needed to reboot the clinical research infrastructure, have investigators refocus on non-COVID-19 activities, and to reinvigorate participants to engage in clinical research. Further, new financial challenges for institutions may reduce protected time for clinician researchers and/or an institution’s capacity to support investigator-initiated clinical trials, as well as potentially limiting the space for the conduct of trials. Yet, there are clearly many positives that have emerged from the COVID-19 experience that improve our capacity to conduct clinical trials, including, as detailed below, how to use technology to facilitate research activities including teleconsenting and videoconferencing of investigator meetings.

Potential Methodologic Changes in Clinical Trial Data Analysis

The disruption to clinical trial procedures by COVID-19 creates analytic challenges given that some planned data will have not been collected. Both the goals of the trial as well as the analysis plan may therefore need to be revised. In conducting statistical analyses and model building, results should be more cautiously interpreted if based on a more limited data set, and sensitivity analyses are needed to determine the robustness of the results in the setting of protocol deviations(12). Imputation methods will also need to be considered to account for missing data(13). To avoid heavy reliance on complicated statistical methods as an adjustment for incomplete data, these challenges motivate us to develop more flexible, non-fixed-sample designs that are capable of extending the trial based on current cumulated data while still keeping the statistical plan rigorous. Adaptive designs are highly desirable for future clinical trials: such designs allow us to update the initial design parameters at the interim stages and re-estimate the sample size based on the data observed in the course of the trial to ensure adequate power. Multiple adaptive designs are available with applicability across all phases of clinical investigation(14).

Clinical Research at the Veterans Administration (VA)

The Veterans Health Administration is the largest and oldest integrated health care system in the United States and is unique in that it has its own federally-funded research program through the VA office.
of Research and Development that supports health research nationwide. The health system serves over 9 million Veterans and research in the system has contributed to changes to clinical practice over decades(15). VA clinical research not only consists of clinical trials (most of them multicenter) but also of health services-related research that, rather than randomizing subjects, randomizes participating VA sites to implementation (or not) of different strategies to improve the care of specific groups of Veterans or to improve performance/quality of care. An important part of VA research is observational analyses of large databases containing clinical information on all Veterans enrolled in VA care, the most important of which is the VA Corporate Data Warehouse (CDW). As mentioned above, the MVP is a national research program to learn how genes, lifestyle and military exposures affect health and illness.

The VA Office of Research and Development (ORD) ceased all in-person recruitment and enrollment in clinical trials as of March 16th, 2020 and measures similar to non-VA clinical trial sites were implemented (e.g. virtual visits and enrollment). Despite this, there will be a delay in the completion and completeness of these studies, and it is foreseen that many of them will require extension with supplementary funds. On the other hand, database research at the VA has expanded in this period to include studies investigating the effect of COVID-19 and its treatment on Veterans. The MVP continued recruitment and enrollment through an online survey assessing Veterans’ experiences with COVID-19, including how the pandemic affects their physical and mental health. In addition, many requests for applications have been put forward from the VA ORD to support efforts related to better understanding, preventing, diagnosing, and treating COVID-19.

Device-Related Research

Device trials represent approximately 10% of all clinical trials – over 34,000 are currently registered on ClinicalTrials.gov(16). Device trials have several unique characteristics that make them especially vulnerable to disruption by the COVID-19 pandemic. Therapeutic or diagnostic device trials may require an FDA-issued investigational device exemption (IDE), are rarely “placebo-controlled”, and may compare the investigational device to an existing technology. Traditionally they have relatively small sample sizes and involve fewer study visits. Further, they may require specialized training or unique expertise.

Depending upon the complexity of the device, device trials and device companies may be less able to cope with trial shutdown due to disruption in supply chain, limited resources, limited capital, and inability to replace key personnel. In contrast to pharmaceutical trials, device trials frequently involve a single critical intervention (e.g. surgical implantation, diagnostic assessment); if this critical intervention is delayed the impact on the trial is substantial. If key personnel at the clinical research center who have
been trained in administration of the device are furloughed or laid-off, training of new personnel may be required, prolonging the time to restarting the device trial. With the decline in numbers of coordinators and investigators able to assess subjects and conduct device trials, sites are left to prioritize studies. As a result, recruitment, enrollment, execution and completion of a device trial may suffer disproportionately.

**FDA perspective and NIH Funded Research**

The FDA(17) and NIH(18) have each posted guidance documents for the conduct of clinical trials during the COVID-19 pandemic. These statements acknowledge that because of the pandemic, for ongoing trials, protocol deviations may be necessary and will depend on many factors, including the intervention involved, the patient population, and environmental circumstances. The overarching principle is that patient safety is of utmost importance and should be used to guide decisions impacting the trial, including recruitment, continuation decisions, patient monitoring, delayed assessments, and investigational product dispensing. Implementation of alternative visit formats, including virtual, phone, or remote contact should be considered, provided the safety of the subject can be assured with these approaches. Further, there will need to be increasing flexibility for testing, assuming the safety of the patient can be assured. Protocol modifications that reduce immediate danger or protect the well-being of the research participants may be implemented before Institutional Review Board (IRB) approval but must be subsequently reported.

Even beyond the pandemic, it appears nearly certain that the complexion of clinical research will undergo lasting change. From a regulatory perspective, flexibility by the FDA toward the acceptance of virtual visits and remote safety monitoring, including lab testing at satellite facilities or even home phlebotomy, will almost certainly need to occur to maintain the viability and attractiveness of clinical trials. This is particularly true in the face of what will be a challenging environment for patient recruitment. Further, the development of surrogate noninvasive endpoints for trials takes on greater urgency, given the even greater reluctance of prospective research subjects to agree to invasive procedures performed at the tertiary care center. For non-interventional studies, the challenges may be daunting, and measures to allow remote or virtual study visits and remote or home sample collection may be essential to permit their continuation.

In light of the uncertainty pertaining to the COVID-19 crisis, there have been various measures to accommodate research expenditures during this pandemic. In response to the inevitable impact of COVID-19 social distancing measures, the NIH has implemented guidance for applicants and recipients of funding to ensure research funding measures are sustained(19). The current pandemic raises concern of potential biases in grant selection because of the impact of the pandemic on feasibility, including
patient recruitment. However, guidance has been issued by the NIH urging reviewers not to factor in COVID-19 related concerns into the scoring of proposals(20).

Real World Database Research

Real world data is generally defined as information acquired outside of controlled clinical trials and can encompass a vast array of sources including medical and pharmacy claims, electronic health records, wearable devices, social media, and observational registries, among others(21). The COVID-19 pandemic has provided immediate opportunities to enlighten the medical community about the clinical course of this illness, whereby most of the earlier reports were descriptive real-world studies of COVID-19 patients hospitalized in hotspot regions of China, Italy, and New York(22-24). These real-world datasets were critical to developing an early, real-time framework for understanding the natural history, risk factors, and best practices for this novel disease, which also helped to inform the design of clinical trials of innovative therapeutics.

The pandemic has also generated many challenges to ongoing real-world research in other disease states. Observational studies that rely on in person medical encounters have been impacted by the restrictions placed on non-emergent medical care at both academic and community outpatient practices. Fewer patient visits translated immediately into less real-world Electronic Health Record (EHR) data and biospecimens being collected and analyzed. Real-world studies were deprioritized when principal investigators were called upon to assist with the overwhelming number of critically ill patients with COVID-19 and research site staff were working from home. Site start-up and activation throughout the US, and especially in Europe, was delayed due to the uncertainty created by the pandemic. Even data from wearable devices and social media were likely impacted by global lockdowns that mandated modification of real-world activities and led to anxiety, decreased physical activity, change in eating habits, and other negative effects.

Despite these initial difficulties during the height of the pandemic, real-world studies are extremely well positioned to adapt to what appears to be the new reality of medical care around the globe. Real-world studies are ideally suited to acquire robust information on safety and effectiveness of drugs to treat COVID-19 under Emergency Use Authorization (EUA) designations or to fulfill post-marketing requirements when the rapidity of approval is paramount but additional safety data are warranted. Indeed, the immediacy of the need for information to help guide management of this aggressive disease resulted in a flood of manuscripts derived from real world data sources, including many describing the effectiveness of therapy for unapproved drugs to treat COVID-19(25-28). Two studies of hydroxychloroquine were retracted by high-impact medical journals after irregularities were identified, raising questions about the balance between data integrity and the review process and the urgency for
disseminating important research that can impact patient outcomes(29, 30). Despite the desire and need to publish key observations that might be relevant to critical health care interventions with potential patient benefit, it remains important to conduct the research as guided by the principles of good clinical practice (GCP).

The unprecedented ramp-up of telehealth will increase a patient’s access and comfort level with these platforms and facilitate the adoption of virtual study visits and procedures, such as electronic consent (eConsent) and completion of patient reported outcome measures. Furthermore, observational studies that utilize data from the EHR can maintain continuity in the remote working environments that will be in place for the foreseeable future; research coordinators can access medical records and complete case report forms from distant locations without compromising the safety of themselves or study participants.

**Biorepository and Biomarker research**

Cohort studies designed to contribute to biorepositories or for the purposes of biomarker and microbiome analyses have been profoundly impacted by the COVID-19 pandemic. While many studies of potentially beneficial investigational products have continued to a limited capacity, non-essential clinical research activities have virtually completely halted. Importantly, as ramp-up plans are put into place, often these studies remain deprioritized, jeopardizing the interpretability of the analyses if there are long periods between collections and/or if clinical events are missed. As a result of this disruption, prospective cohort studies specifically designed to identify or validate biomarkers of disease progression or clinical events could be severely impacted unless remote procedures have been effectively implemented.

There has been a temporary shift in focus in some institutions to biobanking of specimens to study COVID-19 itself. While this may represent a unique opportunity for novel discovery, including among patients with chronic liver disease and liver transplant recipients, the collection, processing and storage of these samples has created unique challenges. While the virus has been detected in blood samples in only limited numbers of confirmed positive patients, fecal and salivary samples being collected for microbiome analyses may have significantly higher quantities of detectable virus(31, 32). Thus, these specimens, unless inactivated, are currently recommended to be processed in biosafety level 3 (BSL-3) facilities(33), very few of which are available at most institutions. As biorepositories eventually increase their activities, because some patients with SARS-CoV-2 infection or viral shedding are asymptomatic, additional consideration may have to be given to the safety of handling specimens more broadly.

Given the minimal risk associated with most biomarker and biorepository studies, remote consenting even once the pandemic is over may be an enduring model. In addition, collection and shipping of specimens from home(34-36) in conjunction with remote ascertainment of applicable clinical
symptoms or outcomes could be an efficient model for some of these studies going forward. This pandemic has led to a swift acceleration in home-based biospecimen sampling, which is even being utilized in the NIH-sponsored population-based SARS-CoV-2 serosurvey(37). These remote procedures will be crucial to ensuring that biorepositories and biomarker studies can fulfill their potential.

Clinical Research in Special Populations

Pediatric Clinical Research

Pediatric liver research has faced unique challenges during this COVID-19 pandemic. Most impacted have been clinical research studies focused on diseases with precise developmental windows for diagnosis and treatment, namely biliary atresia (BA), the most common indication for liver transplantation(38), and other inherited disorders of cholestasis. Studies of BA done under the umbrella of The Childhood Liver Disease Research Network (ChiLDReN), an NIH-funded consortium and biorepository(39), have been largely halted during this pandemic, with no new sample collection. The failure to capture new cases of BA will certainly extend the timeline of progress. More importantly, the diagnosis of BA may be delayed, as parents have been fearful of bringing their infants to their pediatrician’s office during this critical window for BA diagnosis between hospital discharge at birth and 2-month vaccinations.

As in adult liver research, pediatric clinical studies have been subject to inconsistent and conflicting regulatory guidelines from local hospitals and universities to state to federal government. There have been multiple conversations with sponsors and institutions to find a “blended current practice” of telemedicine, labs, and in-person study visits. Intervention studies are often limited in children, but this pandemic risks delayed opening or abandonment of new intervention studies in pediatric NASH and inherited forms of pediatric cholestasis.

Given that many pediatric liver diseases fall under the category of rare disease, we may see the biggest impact of this pandemic and unstable economic times on funding of pediatric liver research. Freestanding children’s hospitals perhaps have been hit the hardest financially as they drastically cut patient flow to prepare for a possible COVID-19 surge and potential co-optation of pediatric spaces for adult COVID-19 patients. Unfortunately, most centers were left with empty hospitals and financial consequences, which will certainly impact decisions on new hires, pilot research grants, and bridge funding for clinician-scientists. In addition, much of pediatric liver research relies on philanthropy and foundation support. As many non-profits see a drastic decrease in donations with unprecedented financial challenges and cancellation of all fundraising events, this will certainly impact pediatric liver research funding.
The pediatric liver community is a small one in comparison to its adult counterparts. Professional networking, especially for trainees and junior faculty, has been affected with cancellation of many scientific meetings. The pandemic may impact the future directions of pediatric liver research with regards to pediatric Non-alcoholic Fatty Liver Disease (NAFLD), acute liver failure, and developmental outcomes research. The emergence of COVID-19 pediatric multisystem inflammatory syndrome reveals similarities with secondary hemophagocytic lymphohistiocytosis and forms of pediatric acute liver failure presentations(40, 41), which may prompt future investigation into overlapping and key regulatory immune pathways in children. Lastly, with social distancing, closure of schools and recreational activities, and less in-person access to developmental therapies, we may see disproportionate changes in developmental outcomes of children with inherited or acquired liver disease(42).

On a positive note, the COVID-19 pandemic has strengthened an already tight-knit pediatric hepatology community. The SPLIT-TTS and NASPGHAN have put forth a joint national registry for COVID-19 in children with chronic liver disease and post-liver transplantation(43). This pandemic has propelled the pediatric liver community to discuss innovative ways in which to safely allow children and their families back into the clinical arena with necessary re-thinking of clinical and research workspaces and behaviors with the goal of maintaining forward progress in pediatric liver research.

Health Disparities and Research in Marginalized Populations

Research involving marginalized populations, such as the homeless, has similarly been impacted by the COVID-19 pandemic. Health disparities in association with COVID-19 have been highlighted in the media and clinical literature(44), primarily in association with race and ethnicity. It is imperative to anticipate that marginalized groups, for example those experiencing homelessness or who inject drugs, will also experience health inequalities during and in the aftermath of the pandemic. Some basic principles are guiding this re-entry planning which hopefully will ensure ongoing and meaningful engagement with these populations: 1) be nimble, flexible, continue to look for alternate ways to perform activities; 2) ensure access to protective and sanitation equipment to prevent disease, through blood borne and sexually transmitted infections, apart from SARS-CoV-2. Syringe service programs should remain “essential”; 3) continue to promote anti-stigma as an essential value to minimize inequalities and social harms; and 4) engage with our participants to find out their priorities and ability to engage in research, recognizing that marginalized populations may have difficulty with access and operational aspects of technology tools.

Research teams have always had to implement “outside-the-box” ideas for working with marginalized populations and now it is even more important than ever to be flexible and cognizant of the community. A significant area of research with marginalized populations includes practice-based
implementation research; for example, assessing models to enhance access to and success with care.
The first challenge of this domain of research will be the effects of clinical care changes. As patients are
seen less frequently and in-person visits are limited, researchers may need to reduce recruitment and
enrollment expectations when working within clinical practice. Research innovations include reducing the
burden of data collection to what is essential to answer focused research questions while environments
must remain “enabling,” allowing for physical distancing and health interventions to work. Throughout the
country, clinical practice with persons experiencing homelessness or injecting drugs has rapidly changed:
outside testing facilities, curbside services, telehealth visits, extended prescriptions and ‘take-homes’,
rapid and home induction of medication for opioid use disorder, are just some examples of the
transformation that clinicians are reporting. These structural changes, mostly aimed at ensuring safe and
effective clinical care with the lowest possible risk burden on patients and providers, would have taken
years to study, test and implement. There will be new opportunities to assess the impact of these
changes.

It remains essential to promote stigma reduction and avoid further marginalization and unintended
social consequences during this time of rapid change. While telemedicine may be challenging because of
lack of knowledge or access to technology, eConsenting by phone or video may need to take more time
with some marginalized populations. Unique language and lexicon changes apply to these populations,
and perhaps should be revisited with patients during the course of the research study to ensure they
comprehend the process and procedures they are being asked to participate in. Remuneration for
research participants is likely to shift from in-person payments to mail, or transfers, and transportation
arrangement may need to be made. Long-term challenges of reaching and including marginalized and
special populations in research should incorporate lessons and some ‘best-practices’ that clinicians have
been developing during the acute phase of the pandemic. In addition, investigators must commit to
increased representation of marginalized populations and underrepresented minorities in clinical research
through partnering with health care delivery organizations that serve these communities. There have been
several reasons for lack of inclusiveness of minorities in clinical research that include, but not limited to
factors such as less access to academic medical centers, lack of transportation, lack of insurance, distrust
of the medical system and clinical research. As we move forward, it is imperative that we make studies
more research-“friendly” by decreasing study-related burdens through remote assessment and care;
however, it remains possible that increased use of technology might have the opposite effect in
marginalized populations. It is of utmost importance to have culturally sensitive approaches to enrollment;
in this regard, enlisting trusted community leaders can help. Extending clinical research from academic
centers to community clinics with dense minority populations may be of added value. Finally, seeking
input and ideas from our participants, those experiencing homelessness or who inject drugs, on the how, where and why of our research to prevent and treat disease and improve health, are important.

Considerations for Early and Mid-Career Investigators

The unprecedented changes in research due to COVID-19 have disproportionately affected early and mid-career investigators. In addition to disruption of research activities, in many centers, early and mid-career clinical investigators and physician scientists have been deployed to clinical settings interrupting research efforts. For those investigators with caregiver responsibilities, COVID-19 has placed additional strain given the increasing scarcity of available childcare. These additional strains have likely disproportionately affected the academic productivity of women compared to men given the unequal burden of domestic work and childcare shouldered by women(45).

Early and mid-career investigators may be particularly vulnerable to the research setbacks created by this period of decreased productivity. For those with career development awards, this is a crucial but limited period of training and mentored research meant to propel them towards independent funding. In response to these challenges, many universities have enacted policies extending probationary periods for tenure or promotions for faculty on research tracks. In addition, the NIH has enacted more flexible policies for research delayed or negatively impacted by COVID-19 by extending budget periods for approved projects and providing for urgent competitive revisions and administrative supplements.

As we enter the next phase of the COVID-19 pandemic, clinical and research duties are likely to wax and wane resulting in intermittent and increased clinical duties with decreased patient recruitment and cohort enrollment. For early career clinical investigators relying on prospective enrollment in clinical trials or biospecimen collection to quickly analyze for preliminary data for larger awards, there will be a need to think outside the box and develop new strategies for patient recruitment, follow-up, and data collection. Further, they can channel their energy towards alternative research endeavors in order to continue to demonstrate academic productivity while some aspects of their research programs remain on hold (Table 2).

The Patient Perspective on Clinical Research

With the biggest barriers being lack of trust or misconception, ongoing communication and reassurance during the COVID-19 pandemic is essential for continued and successful work in clinical research. Many patients are open to testing investigational products or treatments and become saddened when a trial ends abruptly at any phase. Most are heavily invested in their personal health and hopeful
about potential outcomes. Other motives that may contribute to patients’ feelings of letdown during the pandemic might include curtailment of financial compensation, travel to see a medical expert, or the humanitarian aspect of helping patients.

Telemedicine could be thought of as a reassuring aspect of clinical trials and a boost to retention and new recruitment. Apart from an investigational product being delivered to homes, a patient self-monitoring with a phone app, detecting body temperature or taking high tech images of jaundice, would be most welcome by research participants. While there will always be a need for laboratory tests and physical presence in clinics, access through smart phones can be user-friendly and potentially have a higher retention rate(46). In the United States, a patient survey assured that patients trust telemedicine during clinical trials(47). The FDA has launched the MyStudies app, linked with Google Cloud, and sent out new guidelines. Telemedicine use in clinical trials also has the potential to mitigate inequalities through decentralization, electronic consent, and increased awareness of studies, thereby reducing barriers to entry for minorities, as experienced by African Americans(48). By embracing changing technologies, and partnering with research teams and clinicians, all patients can experience the benefits of clinical research for new therapies during and beyond the era of COVID-19.

Innovative Strategies

Despite the challenges, the pandemic has uncovered many opportunities. For clinical research to remain viable in the short term, all stakeholders must embrace new ways of conducting almost every aspect of clinical trials (Figure 2). Strategies such as social media and targeted online ads and online prescreening questionnaires must replace their face-to-face counterparts. We need to establish clinical trial processes that are safe and acceptable during the pandemic. eConsents can do more than facilitate consent from remote locations; the process can be interactive, which may facilitate retention of the information, and can be used to evaluate the subject’s comprehension of the information presented(49).

Steps are being taken to facilitate innovative strategies in clinical trial enrollment and much of the technology to enable remote patient recruitment, enrollment, investigational drug administration, and study measurement already exists. Telehealth in combination with mobile health (mHealth), defined as medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices, can bring biomedical research to the participant’s home(50). These tools can improve convenience, reduce study visits, facilitate online surveys and assessments, increase retention and participation, deliver reminders, enable real-time remote tracking, and enhance participant safety with real-time alerts(51). There are successful examples of entirely web-based remote clinical trials in which participants are recruited via the web, screened for eligibility using online questionnaires, receive study medications shipped directly to their home, and have
laboratory testing in their community(52). Mobile technologies and web-based clinical trial design can recruit large numbers of participants in a short time span with minimal costs(53). Similarly, such technology may address long-standing barriers to clinical research participation, such as the recruitment of subjects from rural and low-income populations(54).

With regards to study parameter measurements, a variety of validated toolkits supported by the NIH(55) are available to enable virtual (online, tablet, etc.) assessment of health-related quality of life, cognitive, and physical symptoms. Apart from remote specimen collection through mobile phlebotomy units, micro sampling techniques that allow for participants to collect their own blood, while not yet available for prime time, are being developed(56). Partnerships can be established with retail community-based pharmacies to provide investigational drugs. For studies that require in-person visits such as radiologic imaging, study procedures can be altered to maximize the impact of this visit by performing additional assessments (e.g. phlebotomy, questionnaires) in the same visit. This will require a nimble research team and careful coordination. Additionally, sponsors can partner with ridesharing services such as Uber and Lyft to help overcome transportation barriers(57). Even more important, clinical trial designs that limit the need to travel and its associated costs can substantially improve subject participation during COVID-19 and improve participation for typically underrepresented populations after COVID-19(58). Finally, study monitoring may transition away from inefficient and expensive on-site source document verification to remote online monitoring of electronic health records(59). We must be mindful that prioritizing mHealth and other technologies can have the undesired effect of exacerbating existing disparities in clinical research, just as the overreliance on telemedicine can potentially widen disparities in clinical care(60).

An effort to reduce the complexity, regulatory burden, and cost of clinical trials is already long overdue(61), and investments in clinical trial redesign will improve efficiency, feasibility, and cost(62). Removing geographic barriers to clinical trial participation will allow a broader range of participants and improve heterogeneity and generalizability(58, 63). Innovative strategies are critical to permit clinical research to proceed during the COVID-19 pandemic, but will also have a long-lasting positive impact on the conduct of clinical trials for the foreseeable future.

**Conclusions and Future Directions**

Every facet of our lives has been changed by COVID-19 and clinical research is no different. As COVID-19 broadly started to hit the US in March 2020, universities announced policies to shut down research that had to be implemented within 2-3 days. The pandemic has caused varying degrees of interruptions in several domains of clinical research both within and outside of the US (Table 3). While many researchers quickly worked out solutions with sponsors, IRBs, investigational drug services, and in
some instances home care services and local laboratories to enable participants in clinical trials to receive study medications and to have some clinical and laboratory monitoring, protocol deviations were inevitable. Fortunately, the FDA recognized these challenges and quickly issued guidance allowing protocol modifications to prioritize patient safety, IRBs promoted and broadened teleconsenting and expedited approval of protocol modifications, and NIH reassured researchers that grant funding periods will be extended to enable research to be completed. Although these measures softened the blow, COVID-19 will have a long-term impact on clinical research and the career of clinical investigators. Completion of clinical trials will be delayed and missing data might affect conclusions of clinical trials as well as observational studies if data at critical time points are missing. Early and mid-career investigators dependent on preliminary data for grant funding and publication of completed studies for promotion will be most affected not only because of the pause on clinical research but also deployment to other clinical services, and for women and men with young children the added responsibilities of home-schooling and child care. For many investigators, decreased activities meant decreased research-related revenue, necessitating lay-off or reduction in effort of staff, making subsequent recovery more difficult.

As states begin to re-open and hospitals are ramping up clinical services, reopening of clinical research lags behind driven by concerns over unnecessary exposure of staff and participants. However, as with all major crises, innovations adopted to provide clinical service and to maintain clinical research during the COVID-19 pandemic can be leveraged to improve efficiency of clinical research in the future (Figure 3). Foremost is the adoption of telemedicine, eConsents, and remote platforms for patient monitoring and data collection. Both in clinical care and in clinical research, restrictions during the COVID-19 pandemic forced an evaluation of what is essential and what is aspirational. These lessons will lead to leaner study designs, lower costs, and reduced burden to participants, without sacrificing science and quality of the study. Physicians and researchers have also learned how to utilize technology to evaluate patients remotely and to document findings electronically. However, access to technology is not uniform and we must make sure that new studies include representative populations regardless of access to and comfort with technology. Further, a team effort and a shared resource platform is likely to reduce costs and sustain research, and also provide young investigators the necessary and critical support to foster their research. This is evident by the rapidly evolving collaborative research environment, including the NIH initiative of public – private and multi-industry partnership, permitting rapid launch of rigorously designed large clinical trials, head-to-head comparison of new therapeutics and vaccines, as well as early investigations into combinations of investigational therapies.

The COVID-19 pandemic created havoc on our lives and on clinical research, but if we all embrace it as a disruptive innovation, we can come out on the other side of the curve with more robust and efficient study designs that will accelerate rather than hinder progress.
References:


20. Amero S. Temporary, Emergency Situations Due to COVID-19 and Application Scores Received During Peer Review. In: Extramural Nexus; 2020.


45. https://www.nature.com/articles/d41586-020-01135-9 AMn.
Figure Legends:

1) Domains of Clinical and Translational Research in Hepatology

2) Innovative Clinical Research Strategies

3) Overview on the current status, re-entry phase and potential future strategies and expectations in clinical research
Acknowledgements:

AASLD COVID-19 Clinical Oversight Subcommittee (COS):

Oren K. Fix, MD, MSc, FAASLD (Co-chair)
Swedish Medical Center, Seattle, WA

Elizabeth C. Verna, MD, MS (Co-chair)
Columbia University, New York, NY

Kimberly A. Brown, MD, FAASLD
Henry Ford Health System, Detroit, MI

Jaime Chu, MD
Icahn School of Medicine at Mt Sinai, NY, NY

Bilal Hameed, MD
University of California, San Francisco, CA

Laura M. Kulik, MD
Northwestern Medicine, Chicago, IL

Ryan M. Kwok, MD
Uniformed Services University, Bethesda, MD

Brendan M. McGuire, MD
University of Alabama, Birmingham, AL

Daniel S. Pratt, MD, FAASLD
Massachusetts General Hospital, Boston, MA

Jennifer C. Price, MD, PhD

This article is protected by copyright. All rights reserved
University of California, San Francisco, CA

Nancy S. Reau, MD, FAASLD
Rush University, Chicago, IL

Mark W. Russo, MD, MPH, FAASLD
Carolinas Medical Center, Charlotte, NC

Michael L. Schilsky, MD, FAASLD
Yale University, New Haven, CT

Norah A. Terrault, MD, MPH, FAASLD
Keck School of Medicine of USC, Los Angeles, CA

Andrew Reynolds (Patient Advocate)

The writing group acknowledges and thanks Professors Stefan Zeuzem and Jonel Trebicka (Germany) Graham Foster (UK), Pietro Lampertico (Italy) Fabien Zoulim (France), Grace Wong (Hong Kong), Jia-Horng Kao (Taiwan), and Dr. Manuel Mendizabal (Argentina) for providing valuable perspective on the status of clinical research in their countries.

Anita Kalluri and Vanessa Weir (helped in collating the document) Thelmelis Abreu (illustrations) and Kathleen Wagner MIPH (co-contributor to part on marginalized population).
Table 1: Domains of Clinical Research and the Changes, Challenges and Opportunities

<table>
<thead>
<tr>
<th>Domain of Research</th>
<th>Initial Changes in COVID-19 Pandemic</th>
<th>Considerations in Re-entry</th>
<th>Long-term Challenges</th>
<th>Innovative Strategies and Opportunities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investigator Initiated (NIH and non-NIH)</td>
<td>Only essential and lifesaving trials being conducted</td>
<td>Gradual and variable reentry</td>
<td>Maintaining research infrastructure – funding and staff</td>
<td>Changes in study design that are investigator and patient friendly</td>
</tr>
<tr>
<td>Pharmaceutical Investigational Product studies</td>
<td>Safety assessments done remotely (telemedicine)</td>
<td>Uncertainty about patient and research staff safety with face to face contact</td>
<td>Meeting enrollment goals</td>
<td>Remote consenting</td>
</tr>
<tr>
<td>Device trials</td>
<td>Challenges in safety assessments due to potential confounder of COVID-19</td>
<td>Delays in recruitment and thus in completion of studies and delayed approval of therapeutics</td>
<td>Impact of patient perspective</td>
<td>Less invasive endpoints</td>
</tr>
<tr>
<td>Veterans Administration</td>
<td>Change in IP delivery (mailing)</td>
<td>Ongoing transition to remote procedures</td>
<td>Widespread protocol modifications</td>
<td>Decrease number of ancillary study requirements</td>
</tr>
<tr>
<td></td>
<td>Protocol deviations</td>
<td></td>
<td>Delays in drug approval for “non-essential” indications</td>
<td>Increased off site phlebotomy and microsampling techniques</td>
</tr>
<tr>
<td></td>
<td>Remote monitoring</td>
<td></td>
<td>Long term follow-up studies disrupted, potentially less patient interest or commitment</td>
<td>Remote monitoring devices-biometrics, PRO assessments</td>
</tr>
<tr>
<td></td>
<td>New recruitment on hold</td>
<td></td>
<td></td>
<td>Flexibility; incorporate ‘meet the participant’ where they’re at philosophy</td>
</tr>
<tr>
<td></td>
<td>Initiation of new studies on hold</td>
<td></td>
<td></td>
<td>Will have essential role in COVID-19</td>
</tr>
<tr>
<td></td>
<td>Shift to COVID-19 studies</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Real-World Data</td>
<td>Decline/halt in patient encounters, therefore decreased data in this period</td>
<td>Ongoing transition to remote procedures</td>
<td>Maintaining research infrastructure – funding and staff</td>
<td>Adapt to new remote procedures</td>
</tr>
<tr>
<td>----------------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------------------------------------</td>
<td>--------------------------------------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td></td>
<td>Remote data entry and data transfers ongoing in some cases</td>
<td>eConsenting</td>
<td>Ongoing concerns about decreased patient encounters, decreased data</td>
<td>Remote consenting</td>
</tr>
<tr>
<td></td>
<td>New studies on hold</td>
<td></td>
<td>Need for diversification of IT approach/data sources to adapt to changes in health care delivery</td>
<td>Increased investment in remote monitoring for endpoints and adverse events</td>
</tr>
<tr>
<td></td>
<td>Shift to COVID-19 studies</td>
<td></td>
<td>Will have essential role in COVID-19 research</td>
<td></td>
</tr>
<tr>
<td>Biorepository and Longitudinal</td>
<td>Largely on hold</td>
<td>May be low priority in re-entry</td>
<td>Maintaining research</td>
<td>Adapt to new remote</td>
</tr>
</tbody>
</table>

This article is protected by copyright. All rights reserved.
<table>
<thead>
<tr>
<th>Biomarker Studies</th>
<th>Pediatrics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shift to remote ascertainment of clinical events</td>
<td>Only essential and lifesaving trials being conducted</td>
</tr>
<tr>
<td>Shift to COVID-19 studies</td>
<td>Safety assessments, monitoring done remotely</td>
</tr>
<tr>
<td>Concerns about safety of handling specimens that may contain SARS-CoV-2 virus</td>
<td>New recruitment on hold</td>
</tr>
<tr>
<td></td>
<td>Possible delay in diagnosis of and study of rare pediatric conditions</td>
</tr>
<tr>
<td></td>
<td>Initiation of new phases</td>
</tr>
<tr>
<td></td>
<td>Gradual and variable reentry</td>
</tr>
<tr>
<td></td>
<td>New recruitment slow</td>
</tr>
<tr>
<td></td>
<td>Ongoing transition to remote procedures</td>
</tr>
<tr>
<td></td>
<td>Reluctance of parents to allow patient encounters due to fears of exposure</td>
</tr>
<tr>
<td></td>
<td>Maintaining research infrastructure – funding and staff</td>
</tr>
<tr>
<td></td>
<td>Meeting enrollment goals</td>
</tr>
<tr>
<td></td>
<td>Impact of missed or late diagnoses</td>
</tr>
<tr>
<td></td>
<td>Ongoing delays in diagnosis of and study of rare pediatric conditions</td>
</tr>
<tr>
<td></td>
<td>Concern about abandonment of sponsored trials</td>
</tr>
<tr>
<td></td>
<td>Changes in study design that are investigator and patient friendly</td>
</tr>
<tr>
<td></td>
<td>Remote consenting</td>
</tr>
<tr>
<td></td>
<td>Less invasive endpoints</td>
</tr>
<tr>
<td></td>
<td>Increased off site phlebotomy</td>
</tr>
<tr>
<td></td>
<td>Flexibility; incorporate ‘meet the participant’ where they’re at philosophy</td>
</tr>
<tr>
<td></td>
<td>Move to remote</td>
</tr>
<tr>
<td>Infrastructure – funding and staff</td>
<td>Meeting enrollment goals</td>
</tr>
<tr>
<td>Shift to remote ascertainment of clinical events</td>
<td>Impact of missed clinical events and collections during pandemic</td>
</tr>
<tr>
<td>Slow resumption in clinical encounters that often drive specimen collection</td>
<td></td>
</tr>
<tr>
<td>Ongoing concerns about safety of handling specimens that may contain SARS-CoV-2</td>
<td></td>
</tr>
<tr>
<td>virus</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Health Disparities and Marginalized Populations</strong></td>
<td><strong>Only essential and lifesaving trials being conducted</strong></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>• New recruitment and initiation of new studies on hold</td>
<td>• Emergence of new disparities in COVID-19 outcomes and in access to telehealth and remote assessments</td>
</tr>
<tr>
<td><strong>Preservation of Health Disparities and Marginalized Populations</strong></td>
<td><strong>Perhaps increased challenges in transition to remote procedures</strong></td>
</tr>
<tr>
<td>• Increased challenges in patient encounters</td>
<td>• Uncertain timeline for initiating new studies</td>
</tr>
<tr>
<td><strong>Maintenance of Health Disparities and Marginalized Populations</strong></td>
<td><strong>Maintaining research infrastructure – funding and staff</strong></td>
</tr>
<tr>
<td>• Meeting enrollment goals</td>
<td>• Impact of unique challenges in this population in terms of resources, access to health care and knowledge of and access to telehealth technology</td>
</tr>
<tr>
<td><strong>Incorporation of Health Disparities and Marginalized Populations</strong></td>
<td><strong>Changes in study design and innovative approaches that are specifically designed for marginalized populations</strong></td>
</tr>
<tr>
<td>• Incorporate study design that parallels clinical care models</td>
<td>• Innovative approaches to remote consenting and endpoint assessment</td>
</tr>
<tr>
<td>• Will have essential role in COVID-19 research</td>
<td><strong>Formation of education, developmental therapies and telehealth for children</strong></td>
</tr>
</tbody>
</table>

- **Studies on hold**
  - Shift to COVID-19 studies

- **Delays in drug approvals for pediatric indications**

- **Safe approaches to study COVID-19 therapies and vaccines among children**

- **Forms of education, developmental therapies and telehealth for children**

- **Only essential and lifesaving trials being conducted**

- **New recruitment and initiation of new studies on hold**

- **Emergence of new disparities in COVID-19 outcomes and in access to telehealth and remote assessments**

- **Perhaps increased challenges in transition to remote procedures**

- **Maintenance of research infrastructure – funding and staff**

- **Meeting enrollment goals**

- **Impact of unique challenges in this population in terms of resources, access to health care and knowledge of and access to telehealth technology**

- **Incorporation of study design that parallels clinical care models**

- **Innovative approaches to remote consenting and endpoint assessment**

- **Will have essential role in COVID-19 research**
<table>
<thead>
<tr>
<th>Early and Mid-Career Investigators</th>
<th>Many studies on hold</th>
<th>Gradual and variable reentry</th>
<th>Maintaining research infrastructure – funding and staff</th>
<th>Adapt to changes to the research environment and modify research goals and structure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less access to resources for remote activities</td>
<td>New recruitment slow</td>
<td>Ongoing transition to remote procedures</td>
<td>Meeting enrollment goals, generating needed preliminary data</td>
<td>Incorporate evolving technology into research proposals</td>
</tr>
<tr>
<td>Precious time in career development plan lost</td>
<td>Ongoing timeline for initiating new studies</td>
<td>Gradual easing of increased clinical responsibilities</td>
<td>Making up time and/or re-programming career development plan</td>
<td>Remote learning for achieving some career development goals</td>
</tr>
<tr>
<td>Deployment to clinical responsibilities</td>
<td>Ongoing shifts in childcare resources</td>
<td>Possibly lasting changes in work-life balance</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Childcare demands</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This article is protected by copyright. All rights reserved
Table 2: Alternative research and scholarly areas of engagement

| 1. | Perform a systematic review and meta-analysis on the area of investigation |
| 2. | Identify gaps in literature on high-quality review articles and approach content experts to co-author review articles |
| 3. | Write clinical research protocols |
| 4. | Have zoom meetings to present your clinical research aims, hypothesis, and research methods |
| 5. | Expand your network of collaboration |
| 6. | Volunteer to serve as a reviewer for journals in the field |
| 7. | Learn how to perform a high-quality peer-review as it builds prestige in the field and editors will start relying on your input over a period of time |
Table 3: The Global Perspective on Clinical Research in Hepatology*

<table>
<thead>
<tr>
<th>Domain of Clinical Research</th>
<th>Europe and U.K.</th>
<th>Asia</th>
<th>South America</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials</td>
<td><strong>Initial changes</strong></td>
<td>• Taiwan: No changes (pre-pandemic state)</td>
<td>• Only essential trials</td>
</tr>
<tr>
<td>(Industry and NIH/Government Agencies)</td>
<td>• France, Italy, Germany and UK: similar to US, only essential trials and shift to COVID-19 studies, remote monitoring of study patients, variable protocol deviations</td>
<td>• Hong Kong: Similar to US with recruitment of new subjects not allowed, study visits of recruited studies allowed after stringent screening for symptoms, travel history and relevant epidemiological links</td>
<td>• Hold on startup of new non-essential trials</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• COVID-19 research mostly limited to observational studies</td>
</tr>
<tr>
<td></td>
<td><strong>Re-entry and long-term strategy</strong></td>
<td>• Taiwan: Not applicable (pre-pandemic state)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Gradual re-entry as in the US</td>
<td>• Hong Kong: similar to US with the exception of remote study procedures which are generally not allowed</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Slower enrollment</td>
<td></td>
<td>• Variable re-entry strategies among South American countries</td>
</tr>
<tr>
<td></td>
<td>• Remote study initiation and monitoring when possible (Germany); need for improved remote study procedures (France)</td>
<td></td>
<td>• Phone and telemedicine follow-up</td>
</tr>
<tr>
<td></td>
<td>• Very slow recovery in countries and regions of high</td>
<td></td>
<td>• If pandemic prolongs, South America will not be an attractive option for new Clinical Trials</td>
</tr>
<tr>
<td>Real World Data</td>
<td>Initial changes</td>
<td>Re-entry and long-term strategy</td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>-----------------</td>
<td>---------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>France, Germany, Italy and UK:</strong></td>
<td>• France, Germany, Italy and UK: decline in patient encounters, remote data entry and data transfers ongoing, shift to COVID-19 studies</td>
<td>• As per US, ongoing transition to remote procedures in France, UK, Germany; positive engagement in data bases in the UK</td>
<td></td>
</tr>
<tr>
<td><strong>New studies on hold in France and Italy; slower to initiate in Germany</strong></td>
<td></td>
<td>• Limited room for remote procedures in Italy</td>
<td></td>
</tr>
<tr>
<td><strong>Hong Kong:</strong></td>
<td>• Taiwan: decline in patient encounters and decreased data generation during this period</td>
<td>• In Germany, Italy, and France, as per US, maintaining research infrastructure</td>
<td></td>
</tr>
<tr>
<td><strong>similar to US</strong></td>
<td>• Hong Kong: similar to US</td>
<td>• In Germany and France, as per US, need for diversification of IT approach</td>
<td></td>
</tr>
<tr>
<td><strong>ongoing datasets have continued, albeit with reduced inclusion rate.</strong></td>
<td>• Difficult to assess. Huge economic crisis in the region.</td>
<td>• Many training fellowship programs closed this year. Thus, increased staff clinical duties.</td>
<td></td>
</tr>
<tr>
<td><strong>Shift to COVID-19 registries</strong></td>
<td>• On-going datasets have continued, albeit with reduced inclusion rate.</td>
<td>• Research funding resources transferred to cover salaries.</td>
<td></td>
</tr>
<tr>
<td><strong>Taiwan:</strong></td>
<td>• On-going datasets have continued, albeit with reduced inclusion rate.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biorepository, Natural History and Biomarker studies</td>
<td>Initial changes</td>
<td>Re-entry and long-term strategy</td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------------</td>
<td>-----------------</td>
<td>---------------------------------</td>
<td></td>
</tr>
</tbody>
</table>
| • Shift to COVID-19 studies in France, Germany, Italy and the UK | • France, Germany, Italy and UK: largely on hold except HCC studies in France and advanced liver disease in Germany  
• Similar to US in shift to remote ascertainment of clinical events and in concerns with specimen collection (France, Germany, Italy) | • Taiwan: No changes (pre-pandemic state)  
• Hong Kong: shift to remote ascertainment of clinical events |
| • This area is far less developed than in other regions.  
• Virology laboratory shift to COVID-19 testing, limiting other activities. | • Taiwan: No changes (pre-pandemic state)  
• Hong Kong: specimen collection impacted by patient perspective and decreased clinical visits |
<p>| • Still struggling because of COVID-19 pandemic; no real strategy at the moment. |</p>
<table>
<thead>
<tr>
<th></th>
<th>clinic visits. In Italy, small impact of patient perspective or decrease in clinic visits</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Similar to US, develop innovative remote monitoring and assessment strategies (France and Germany); none planned in Italy or UK</td>
<td></td>
</tr>
</tbody>
</table>

*Based on valuable contributions from Professors Stefan Zeuzem and Jonel Trebicka (Germany) Graham Foster (UK), Pietro Lampertico (Italy) Fabien Zoulim (France), Grace Wong (Hong Kong), Jia-Horng Kao (Taiwan), and Dr. Manuel Mendizabal (Argentina)*
Figure 1. Domains of Clinical and Translational Research in Hepatology

Clinical and Translational Research in Hepatology

- Real World Database Research
- Biorepository Longitudinal Studies
- Veterans Health Administration
- Young Investigators Research
- Pediatric Clinical Research
- Investigational Product Interventional Trials
- Medical Device Studies
- Special Populations Health Disparities Underrepresented minorities Patient-Oriented Research

hep_31491_f1.eps

This article is protected by copyright. All rights reserved
Innovative Clinical Research Strategies

Figure 2

Team-based approach to support young investigators
Cross-disciplinary infrastructure resource sharing

REMOTE PHLEBOTOMY/BIOSPECIMEN COLLECTION/RADIOLOGY SERVICES
COMMUNITY PHARMACY FOR INVESTIGATIONAL DRUGS
SATELLITE RECRUITMENT SITES
RESEARCH COORDINATOR & CLINICAL INVESTIGATOR
VIDEOCONFERENCE STUDY VISIT
REMOTE EXTERNAL MONITORING
ELECTRONIC HEALTH RECORD
REMOTE PATIENT MONITORING

hep_31491_f2.eps
Figure 3. Overview of early pandemic phase, re-entry phase, and potential long-term strategies in clinical research

Phase 1
(Early pandemic phase)
- Non-essential trials held
- Sudden need to adapt to changes such as in research infrastructure, remote monitoring, safety assessments, IP delivery at home
- Shift to COVID-19 research
- Biorepository and real world database research on hold
- Young Investigators research on hold and compounded by unique challenges in personal lives involving childcare, home schooling, and shifted clinical responsibilities
- Decrease in philanthropy and institutional research funding

Phase 2
(Re-entry phase)
- Variable re-entry into various domains of research; priorities set
- Research infrastructure changes due to financial constrains
- Consolidation phase in preparation for long-term changes to clinical research study design and procedures
- Young Investigators-creativity in making up lost time and/or re-programming career advancement timelines
- Build on COVID-19 research and on lessons learned

Phase 3
(Long term strategy)
- Innovation and creativity in study design and end points
- Creativity in mentoring Young Investigators on intermediate and long-term research ideas and timelines
- Shifting study design paradigms while maintaining study integrity
- Buy-in by sponsors, regulatory authorities, and NIH in adapting to the changing environment
- Hybrid model of on-site and remote strategies for achieving study goals
- Consolidate information technology